Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
Summary Background Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines. Aims To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD. Methods We cond...
Saved in:
Published in | Alimentary pharmacology & therapeutics Vol. 60; no. 6; pp. 686 - 700 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.09.2024
|
Subjects | |
Online Access | Get full text |
ISSN | 0269-2813 1365-2036 1365-2036 |
DOI | 10.1111/apt.18194 |
Cover
Abstract | Summary
Background
Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.
Aims
To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.
Methods
We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023. All studies were included from the MEDLINE database via PubMed.
Results
For Crohn's disease, we included eight randomised controlled trials (RCTs) and 17 observational studies. Parenteral methotrexate effectively increased remission rates in steroid‐dependent patients at 25 mg/week for 16 weeks and at 15 mg/week for maintenance. Methotrexate can be used in combination with anti‐tumour necrosis factor (TNF) agents to reduce immunogenicity. Data comparing thiopurines and methotrexate remain scarce. For ulcerative colitis (UC), we included five RCTs and 10 observational studies were included; there was no evidence to support the use of methotrexate in (UC). We extracted safety data from 17 studies; mild‐to‐moderate adverse effects were common. The incidence of liver fibrosis or cirrhosis was low.
Conclusion
Methotrexate is effective at inducing and maintaining remission in steroid‐refractory Crohn's disease and can reduce anti‐TNF‐induced immunogenicity when used in combination therapy. Data regarding tolerance and safety are reassuring. These findings challenge preconceived ideas on methotrexate and suggest that it is a valid first‐line conventional option for the treatment of mild‐to‐moderate Crohn's disease. |
---|---|
AbstractList | Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.
To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.
We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023. All studies were included from the MEDLINE database via PubMed.
For Crohn's disease, we included eight randomised controlled trials (RCTs) and 17 observational studies. Parenteral methotrexate effectively increased remission rates in steroid-dependent patients at 25 mg/week for 16 weeks and at 15 mg/week for maintenance. Methotrexate can be used in combination with anti-tumour necrosis factor (TNF) agents to reduce immunogenicity. Data comparing thiopurines and methotrexate remain scarce. For ulcerative colitis (UC), we included five RCTs and 10 observational studies were included; there was no evidence to support the use of methotrexate in (UC). We extracted safety data from 17 studies; mild-to-moderate adverse effects were common. The incidence of liver fibrosis or cirrhosis was low.
Methotrexate is effective at inducing and maintaining remission in steroid-refractory Crohn's disease and can reduce anti-TNF-induced immunogenicity when used in combination therapy. Data regarding tolerance and safety are reassuring. These findings challenge preconceived ideas on methotrexate and suggest that it is a valid first-line conventional option for the treatment of mild-to-moderate Crohn's disease. BackgroundMethotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.AimsTo review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.MethodsWe conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023. All studies were included from the MEDLINE database via PubMed.ResultsFor Crohn's disease, we included eight randomised controlled trials (RCTs) and 17 observational studies. Parenteral methotrexate effectively increased remission rates in steroid‐dependent patients at 25 mg/week for 16 weeks and at 15 mg/week for maintenance. Methotrexate can be used in combination with anti‐tumour necrosis factor (TNF) agents to reduce immunogenicity. Data comparing thiopurines and methotrexate remain scarce. For ulcerative colitis (UC), we included five RCTs and 10 observational studies were included; there was no evidence to support the use of methotrexate in (UC). We extracted safety data from 17 studies; mild‐to‐moderate adverse effects were common. The incidence of liver fibrosis or cirrhosis was low.ConclusionMethotrexate is effective at inducing and maintaining remission in steroid‐refractory Crohn's disease and can reduce anti‐TNF‐induced immunogenicity when used in combination therapy. Data regarding tolerance and safety are reassuring. These findings challenge preconceived ideas on methotrexate and suggest that it is a valid first‐line conventional option for the treatment of mild‐to‐moderate Crohn's disease. Summary Background Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines. Aims To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD. Methods We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023. All studies were included from the MEDLINE database via PubMed. Results For Crohn's disease, we included eight randomised controlled trials (RCTs) and 17 observational studies. Parenteral methotrexate effectively increased remission rates in steroid‐dependent patients at 25 mg/week for 16 weeks and at 15 mg/week for maintenance. Methotrexate can be used in combination with anti‐tumour necrosis factor (TNF) agents to reduce immunogenicity. Data comparing thiopurines and methotrexate remain scarce. For ulcerative colitis (UC), we included five RCTs and 10 observational studies were included; there was no evidence to support the use of methotrexate in (UC). We extracted safety data from 17 studies; mild‐to‐moderate adverse effects were common. The incidence of liver fibrosis or cirrhosis was low. Conclusion Methotrexate is effective at inducing and maintaining remission in steroid‐refractory Crohn's disease and can reduce anti‐TNF‐induced immunogenicity when used in combination therapy. Data regarding tolerance and safety are reassuring. These findings challenge preconceived ideas on methotrexate and suggest that it is a valid first‐line conventional option for the treatment of mild‐to‐moderate Crohn's disease. Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.BACKGROUNDMethotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.AIMSTo review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023. All studies were included from the MEDLINE database via PubMed.METHODSWe conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023. All studies were included from the MEDLINE database via PubMed.For Crohn's disease, we included eight randomised controlled trials (RCTs) and 17 observational studies. Parenteral methotrexate effectively increased remission rates in steroid-dependent patients at 25 mg/week for 16 weeks and at 15 mg/week for maintenance. Methotrexate can be used in combination with anti-tumour necrosis factor (TNF) agents to reduce immunogenicity. Data comparing thiopurines and methotrexate remain scarce. For ulcerative colitis (UC), we included five RCTs and 10 observational studies were included; there was no evidence to support the use of methotrexate in (UC). We extracted safety data from 17 studies; mild-to-moderate adverse effects were common. The incidence of liver fibrosis or cirrhosis was low.RESULTSFor Crohn's disease, we included eight randomised controlled trials (RCTs) and 17 observational studies. Parenteral methotrexate effectively increased remission rates in steroid-dependent patients at 25 mg/week for 16 weeks and at 15 mg/week for maintenance. Methotrexate can be used in combination with anti-tumour necrosis factor (TNF) agents to reduce immunogenicity. Data comparing thiopurines and methotrexate remain scarce. For ulcerative colitis (UC), we included five RCTs and 10 observational studies were included; there was no evidence to support the use of methotrexate in (UC). We extracted safety data from 17 studies; mild-to-moderate adverse effects were common. The incidence of liver fibrosis or cirrhosis was low.Methotrexate is effective at inducing and maintaining remission in steroid-refractory Crohn's disease and can reduce anti-TNF-induced immunogenicity when used in combination therapy. Data regarding tolerance and safety are reassuring. These findings challenge preconceived ideas on methotrexate and suggest that it is a valid first-line conventional option for the treatment of mild-to-moderate Crohn's disease.CONCLUSIONMethotrexate is effective at inducing and maintaining remission in steroid-refractory Crohn's disease and can reduce anti-TNF-induced immunogenicity when used in combination therapy. Data regarding tolerance and safety are reassuring. These findings challenge preconceived ideas on methotrexate and suggest that it is a valid first-line conventional option for the treatment of mild-to-moderate Crohn's disease. |
Author | Loeuille, Damien Peyrin‐Biroulet, Laurent Caron, Bénédicte Danese, Silvio Sibilia, Jean Sequier, Léa Jairath, Vipul Netter, Patrick Honap, Sailish |
Author_xml | – sequence: 1 givenname: Léa surname: Sequier fullname: Sequier, Léa organization: Saint‐Éloi Hospital – sequence: 2 givenname: Bénédicte surname: Caron fullname: Caron, Bénédicte organization: FHU‐CURE, Nancy University Hospital – sequence: 3 givenname: Damien surname: Loeuille fullname: Loeuille, Damien organization: University of Lorraine – sequence: 4 givenname: Sailish orcidid: 0000-0001-6657-2763 surname: Honap fullname: Honap, Sailish organization: King's College London – sequence: 5 givenname: Vipul orcidid: 0000-0002-1092-0033 surname: Jairath fullname: Jairath, Vipul organization: Western University – sequence: 6 givenname: Patrick surname: Netter fullname: Netter, Patrick organization: University of Lorraine – sequence: 7 givenname: Silvio orcidid: 0000-0001-7341-1351 surname: Danese fullname: Danese, Silvio organization: Università Vita‐Salute San Raffaele – sequence: 8 givenname: Jean surname: Sibilia fullname: Sibilia, Jean organization: Université de Strasbourg – sequence: 9 givenname: Laurent orcidid: 0000-0003-2536-6618 surname: Peyrin‐Biroulet fullname: Peyrin‐Biroulet, Laurent email: peyrinbiroulet@gmail.com organization: FHU‐CURE, Nancy University Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39076140$$D View this record in MEDLINE/PubMed |
BookMark | eNp90c1qFTEUB_AgLfa2uvAFJOBGF9MmmZkk4-5SrAotCtb1kI8zmJKZXJNMr7PzIfqEPolpb-uiYEMgBH7nT3LOIdqbwgQIvaLkmJZ1ojb5mEraNc_Qita8rRip-R5aEca7iklaH6DDlK4IIVwQ9hwd1B0RnDZkhfy3JWUYVXYGR7h2sH2PLyD_CDnCL5Xhz--bNd6EEP2C58lCTDkEi9Vkd9c5gcUjWGdKRJiwu92DV2OJDHHBOmzBY-sSqAQv0P6gfIKX9-cR-n724fL0U3X-5ePn0_V5ZWopm0q0hosGai2VIES0EpSmAwPOZSsHYS2Tg2TCGEu10IpoQ7RkStF26IhSuj5Cb3e5mxh-zpByP7pkwHs1QZhTXxPJCW8kk4W-eUSvwhyn8rqiOtF0gvOmqNf3atbls_0mulHFpX_oYwHvdsDEkFKE4R-hpL-dUV9m1N_NqNiTR9a4fNe9HJXzT1VsnYfl_9H9-uvlruIvgGuk8g |
CitedBy_id | crossref_primary_10_1016_S2468_1253_24_00355_8 crossref_primary_10_1016_j_bpg_2025_101994 |
Cites_doi | 10.1053/gast.1996.v110.pm8613046 10.1111/j.1365‐2133.2008.08876.x 10.1097/00042737‐200012110‐00010 10.1016/j.jaad.2017.06.043 10.1111/apt.12161 10.1007/s10620‐018‐5422‐8 10.1111/j.1365‐2036.2011.04925.x 10.1097/MEG.0b013e3283556db5 10.1016/s1590‐8658(03)00372‐4 10.1016/j.crohns.2007.11.002 10.1634/theoncologist.2015‐0164 10.1111/j.1365‐2036.2005.02331.x 10.3390/jcm12134382 10.1038/ajg.2018.27 10.1002/14651858.CD000951.pub2 10.4292/wjgpt.v7.i1.51 10.1016/j.jhep.2022.12.034 10.1016/S2468‐1253(19)30012‐3 10.1002/1529‐0131(200107)44:7<1515::AID‐ART273>3.0.CO;2‐7 10.1093/ecco‐jcc/jjv027 10.1046/j.1365‐2036.2002.01227.x 10.1093/ecco‐jcc/jjab178 10.1016/j.cgh.2012.12.026 10.1093/ecco‐jcc/jjv141 10.1053/j.gastro.2006.04.049 10.1046/j.1365‐2036.1997.00175.x 10.1002/14651858.CD000957.pub2 10.1111/bjd.14816 10.1016/j.cgh.2019.02.043 10.1177/17562848221085889 10.1111/apt.17719 10.1136/gut.2010.212712 10.1053/j.gastro.2013.09.035 10.1053/j.gastro.2008.01.012 10.1053/j.gastro.2020.08.060 10.1136/ard.2008.094474 10.1093/rheumatology/keab313 10.1111/jgh.12015 10.1177/2040622315608647 10.1093/ecco‐jcc/jjz020 10.1053/j.gastro.2021.07.042 10.1016/j.semarthrit.2010.04.003 10.1177/1756284818817293 10.1016/j.crohns.2011.03.012 10.1097/MIB.0000000000000589 10.1097/01.MIB.0000209787.19952.53 10.1177/1753495X20919214 10.1053/j.gastro.2013.11.024 10.1182/blood.v99.11.3909 10.1001/archderm.1980.01640260091025 10.1007/s00384‐023‐04349‐1 10.1136/gut.2006.099978 10.1177/17562848211043017 10.1038/ncpgasthep0796 10.1001/jama.2017.16071 10.1159/000482007 10.3109/00365521.2011.647412 10.1053/j.gastro.2018.06.046 10.1002/art.23835 10.1016/j.jaad.2016.08.022 10.1002/acr.24596 10.1093/rheumatology/kew479 10.1002/ibd.21820 10.1093/ecco‐jcc/jjw188 10.1111/j.1440‐1746.2007.05006.x 10.1016/j.jhep.2023.02.018 10.1056/NEJM199502023320503 10.1053/j.gastro.2015.10.050 10.1007/s10067‐022‐06221‐z 10.1182/blood.V4.2.160.160 10.1016/j.jaad.2020.02.044 10.1111/j.1365‐2036.2009.04073.x 10.3748/wjg.v23.i32.5836 10.1093/ibd/izy047 10.1038/s41584‐022‐00883‐4 10.1007/s11938‐017‐0128‐0 10.3390/jcm10020364 10.1038/ajg.2010.343 10.1016/j.jaad.2009.03.027 10.7326/0003‐4819‐110‐5‐353 10.1093/ecco‐jcc/jjad108 10.1136/pmj.76.902.787 10.3390/jcm12062432 10.1016/j.clnu.2022.12.004 10.1016/j.autrev.2013.06.005 10.1093/ecco‐jcc/jjz180 10.1371/journal.pone.0194401 10.3748/wjg.v25.i30.4158 10.1111/apt.13862 10.1093/rheumatology/35.5.453 10.1136/pgmj.2009.085787 10.1371/journal.pone.0221823 10.1111/apt.16039 10.4065/71.1.69 10.1111/j.1572‐0241.2000.02190.x 10.3899/jrheum.100600 10.1136/gutjnl‐2020‐322129 10.1136/ard‐2022‐223296 10.1016/j.dld.2011.09.015 10.1111/j.1365‐2036.2006.02929.x 10.1002/art.38368 10.1056/NEJM200006013422202 10.1093/ecco‐jcc/jjaa050 10.1136/gut.2005.081950b 10.1097/RHU.0000000000000810 10.1016/j.cgh.2020.07.012 10.1053/j.gastro.2012.05.004 10.1093/rheumatology/kep291 |
ContentType | Journal Article |
Copyright | 2024 John Wiley & Sons Ltd. 2024 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. Copyright © 2024 John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2024 John Wiley & Sons Ltd. – notice: 2024 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. – notice: Copyright © 2024 John Wiley & Sons Ltd. |
DBID | 24P AAYXX CITATION NPM 7T5 7TK 7U9 H94 K9. M7N 7X8 |
DOI | 10.1111/apt.18194 |
DatabaseName | Wiley Online Library Open Access (Activated by CARLI) CrossRef PubMed Immunology Abstracts Neurosciences Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Neurosciences Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
DatabaseTitleList | PubMed AIDS and Cancer Research Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access (Activated by CARLI) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2036 |
EndPage | 700 |
ExternalDocumentID | 39076140 10_1111_apt_18194 APT18194 |
Genre | reviewArticle Journal Article Review |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AFBPY AFEBI AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT AAHHS AAYXX ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CITATION NPM 7T5 7TK 7U9 H94 K9. M7N 7X8 |
ID | FETCH-LOGICAL-c3884-75c674e3b8a700758eab1f2e66858f7dd28f827ccd1b7ba0bc0b82aa15f90aab3 |
IEDL.DBID | DR2 |
ISSN | 0269-2813 1365-2036 |
IngestDate | Fri Sep 05 09:55:57 EDT 2025 Fri Jul 25 09:52:14 EDT 2025 Mon Jul 21 06:00:55 EDT 2025 Thu Apr 24 22:56:15 EDT 2025 Tue Jul 01 02:22:44 EDT 2025 Sun Jul 06 04:45:09 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
License | 2024 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3884-75c674e3b8a700758eab1f2e66858f7dd28f827ccd1b7ba0bc0b82aa15f90aab3 |
Notes | The Handling Editor for this article was Professor Cynthia Seow, and this uncommissioned review was accepted for publication after full peer‐review. Correction added on 6 August 2024, after first online publication: The copyright line was changed. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0001-7341-1351 0000-0002-1092-0033 0000-0001-6657-2763 0000-0003-2536-6618 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fapt.18194 |
PMID | 39076140 |
PQID | 3097497664 |
PQPubID | 2045200 |
PageCount | 15 |
ParticipantIDs | proquest_miscellaneous_3086064828 proquest_journals_3097497664 pubmed_primary_39076140 crossref_primary_10_1111_apt_18194 crossref_citationtrail_10_1111_apt_18194 wiley_primary_10_1111_apt_18194_APT18194 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | September 2024 |
PublicationDateYYYYMMDD | 2024-09-01 |
PublicationDate_xml | – month: 09 year: 2024 text: September 2024 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Chichester |
PublicationTitle | Alimentary pharmacology & therapeutics |
PublicationTitleAlternate | Aliment Pharmacol Ther |
PublicationYear | 2024 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2002; 16 2017; 318 2023; 78 2019; 13 2019; 12 1989; 110 2019; 14 2002; 99 1999; 46 2019; 17 2021; 160 1996; 71 2000; 95 2020; 14 2021; 161 2012; 18 2006; 55 Suppl 1 2001; 44 2021; 73 2023; 82 2021; 70 2006; 23 2013; 2013 2000; 12 2017; 76 2019; 25 2008; 23 2014; 13 2007; 4 2012; 24 2016; 150 1980; 116 2009; 68 2019; 4 2023; 58 2009; 61 2003; 35 2008; 59 2014; 2014 2012; 35 2011; 5 2010; 40 2018; 24 2023; 42 2016; 7 2018; 113 2000; 76 2017; 56 2016; 21 2022; 15 1996; 110 2000; 342 2008; 134 2012; 47 2021; 61 2012; 44 2022; 16 2016; 175 2018; 13 2014; 146 2016; 22 2010; 59 2013; 28 2009; 160 2023; 38 1949; 4 2017; 45 2005; 21 2006; 131 1995; 332 2008; 2 1996; 35 2014; 66 2009; 48 1997; 92 2013; 11 1997; 11 2019; 64 2020; 52 2011; 24 2018; 78 2015; 6 2012; 143 2023; 12 2006; 12 2023; 18 2020; 82 2023; 19 2017; 23 2013; 145 2022; 41 2015; 9 2011; 38 2007; 56 1998; 25 2021; 14 2018; 155 2010; 86 2017; 96 2009; 30 2013; 37 2021; 10 2011; 106 2017; 15 2017; 11 2021; 19 e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_40_1 e_1_2_10_109_1 Ortiz Z (e_1_2_10_42_1) 1998; 25 e_1_2_10_70_1 e_1_2_10_93_1 e_1_2_10_2_1 e_1_2_10_74_1 e_1_2_10_97_1 e_1_2_10_6_1 e_1_2_10_55_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_78_1 e_1_2_10_112_1 e_1_2_10_13_1 e_1_2_10_32_1 e_1_2_10_51_1 e_1_2_10_82_1 e_1_2_10_29_1 e_1_2_10_63_1 e_1_2_10_86_1 e_1_2_10_105_1 e_1_2_10_25_1 e_1_2_10_48_1 e_1_2_10_67_1 e_1_2_10_101_1 e_1_2_10_45_1 e_1_2_10_22_1 e_1_2_10_41_1 e_1_2_10_90_1 e_1_2_10_71_1 e_1_2_10_94_1 e_1_2_10_52_1 e_1_2_10_3_1 e_1_2_10_75_1 e_1_2_10_113_1 e_1_2_10_38_1 e_1_2_10_98_1 e_1_2_10_56_1 e_1_2_10_79_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_10_1 e_1_2_10_33_1 Arora S (e_1_2_10_19_1) 1999; 46 e_1_2_10_60_1 e_1_2_10_106_1 e_1_2_10_83_1 e_1_2_10_64_1 e_1_2_10_102_1 e_1_2_10_49_1 e_1_2_10_87_1 e_1_2_10_26_1 e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_69_1 e_1_2_10_110_1 e_1_2_10_91_1 e_1_2_10_72_1 e_1_2_10_95_1 e_1_2_10_4_1 e_1_2_10_53_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_76_1 e_1_2_10_99_1 e_1_2_10_114_1 e_1_2_10_8_1 e_1_2_10_57_1 e_1_2_10_58_1 e_1_2_10_34_1 e_1_2_10_11_1 e_1_2_10_30_1 e_1_2_10_80_1 e_1_2_10_61_1 e_1_2_10_84_1 e_1_2_10_107_1 e_1_2_10_27_1 e_1_2_10_65_1 e_1_2_10_88_1 e_1_2_10_103_1 e_1_2_10_24_1 e_1_2_10_43_1 e_1_2_10_20_1 e_1_2_10_108_1 e_1_2_10_92_1 e_1_2_10_73_1 e_1_2_10_115_1 e_1_2_10_96_1 e_1_2_10_54_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_77_1 e_1_2_10_111_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_59_1 e_1_2_10_31_1 Voulgari PV (e_1_2_10_68_1) 2011; 24 e_1_2_10_50_1 Oren R (e_1_2_10_18_1) 1997; 92 e_1_2_10_81_1 e_1_2_10_62_1 e_1_2_10_104_1 e_1_2_10_85_1 e_1_2_10_28_1 e_1_2_10_66_1 e_1_2_10_100_1 e_1_2_10_47_1 e_1_2_10_89_1 |
References_xml | – volume: 44 start-page: 123 issue: 2 year: 2012 end-page: 127 article-title: The use of methotrexate for treatment of inflammatory bowel disease in clinical practice publication-title: Dig Liver Dis – volume: 38 start-page: 54 issue: 1 year: 2023 article-title: Immunomodulator comedication promotes the reversal of anti‐drug antibody‐mediated loss of response to anti‐TNF therapy in inflammatory bowel disease publication-title: Int J Color Dis – volume: 70 start-page: 796 issue: 4 year: 2021 end-page: 802 article-title: Emerging treatment options for extraintestinal manifestations in IBD publication-title: Gut – volume: 42 start-page: 352 issue: 3 year: 2023 end-page: 379 article-title: ESPEN guideline on clinical nutrition in inflammatory bowel disease publication-title: Clin Nutr – volume: 14 start-page: 1354 issue: 10 year: 2020 end-page: 1363 article-title: Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease‐related complications publication-title: J Crohns Colitis – volume: 59 start-page: 996 issue: 7 year: 2008 end-page: 1001 article-title: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action publication-title: Arthritis Rheum – volume: 16 start-page: 2 issue: 1 year: 2022 end-page: 17 article-title: ECCO guidelines on therapeutics in ulcerative colitis: medical treatment publication-title: J Crohns Colitis – volume: 55 Suppl 1 start-page: i16 year: 2006 end-page: i35 article-title: European evidence based consensus on the diagnosis and management of Crohn's disease: current management publication-title: Gut – volume: 82 start-page: 1445 issue: 6 year: 2020 end-page: 1486 article-title: Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies publication-title: J Am Acad Dermatol – volume: 110 start-page: 1416 issue: 5 year: 1996 end-page: 1421 article-title: Methotrexate in chronic active ulcerative colitis: a double‐blind, randomized Israeli Multicenter Trial publication-title: Gastroenterology – volume: 4 start-page: 277 issue: 5 year: 2007 end-page: 287 article-title: Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis publication-title: Nat Clin Pract Gastroenterol Hepatol – volume: 11 start-page: 667 issue: 6 year: 2013 end-page: 672 article-title: Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn's disease publication-title: Clin Gastroenterol Hepatol – volume: 2013 issue: 5 year: 2013 article-title: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis publication-title: Cochrane Database Syst Rev – volume: 318 start-page: 1679 issue: 17 year: 2017 end-page: 1686 article-title: Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease publication-title: JAMA – volume: 23 start-page: 954 issue: 6 year: 2008 end-page: 958 article-title: A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration publication-title: J Gastroenterol Hepatol – volume: 38 start-page: 628 issue: 4 year: 2011 end-page: 632 article-title: Paternal exposure to methotrexate and pregnancy outcomes publication-title: J Rheumatol – volume: 11 start-page: 263 issue: 3 year: 2017 end-page: 273 article-title: European Crohn's and colitis organisation topical review on IBD in the elderly publication-title: J Crohns Colitis – volume: 92 start-page: 2203 issue: 12 year: 1997 end-page: 2209 article-title: Methotrexate in chronic active Crohn's disease: a double‐blind, randomized Israeli multicenter trial publication-title: Am J Gastroenterol – volume: 12 year: 2019 article-title: Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? publication-title: Therap Adv Gastroenterol – volume: 76 start-page: 40 issue: 1 year: 2017 end-page: 48 article-title: Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population‐based cross‐sectional study publication-title: J Am Acad Dermatol – volume: 23 start-page: 1621 issue: 11 year: 2006 end-page: 1628 article-title: Diagnosis of liver fibrosis by transient elastography (FibroScan) and non‐invasive methods in Crohn's disease patients treated with methotrexate publication-title: Aliment Pharmacol Ther – volume: 71 start-page: 69 issue: 1 year: 1996 end-page: 80 article-title: Methotrexate for inflammatory bowel disease: pharmacology and preliminary results publication-title: Mayo Clin Proc – volume: 21 start-page: 1471 issue: 12 year: 2016 end-page: 1482 article-title: Preventing and managing toxicities of high‐dose methotrexate publication-title: Oncologist – volume: 13 start-page: 15 issue: 1 year: 2014 end-page: 19 article-title: Paradoxical immune‐mediated inflammation in inflammatory bowel disease patients receiving anti‐TNF‐α agents publication-title: Autoimmun Rev – volume: 47 start-page: 575 issue: 5 year: 2012 end-page: 579 article-title: Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial publication-title: Scand J Gastroenterol – volume: 58 start-page: 1151 issue: 11–12 year: 2023 end-page: 1162 article-title: Therapeutic drug monitoring of methotrexate in patients with Crohn's disease publication-title: Aliment Pharmacol Ther – volume: 48 start-page: 1575 issue: 12 year: 2009 end-page: 1580 article-title: Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients publication-title: Rheumatology (Oxford) – volume: 13 issue: 3 year: 2018 article-title: Dermatological guidelines for monitoring methotrexate treatment reduce drug‐survival compared to rheumatological guidelines publication-title: PLoS One – volume: 45 start-page: 276 issue: 2 year: 2017 end-page: 282 article-title: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab publication-title: Aliment Pharmacol Ther – volume: 15 start-page: 84 issue: 1 year: 2017 end-page: 104 article-title: Thiopurines and methotrexate use in IBD patients in a biologic era publication-title: Curr Treat Options Gastroenterol – volume: 131 start-page: 283 issue: 1 year: 2006 end-page: 311 article-title: American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy publication-title: Gastroenterology – volume: 10 issue: 2 year: 2021 article-title: Dermatological manifestations in inflammatory bowel diseases publication-title: J Clin Med – volume: 12 start-page: 1227 issue: 11 year: 2000 end-page: 1233 article-title: 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease publication-title: Eur J Gastroenterol Hepatol – volume: 332 start-page: 292 issue: 5 year: 1995 end-page: 297 article-title: Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators publication-title: N Engl J Med – volume: 73 start-page: 924 issue: 7 year: 2021 end-page: 939 article-title: 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis publication-title: Arthritis Care Res – volume: 12 issue: 13 year: 2023 article-title: The role of low‐dose Oral methotrexate in increasing anti‐TNF drug levels and reducing immunogenicity in IBD publication-title: J Clin Med – volume: 113 start-page: 481 issue: 4 year: 2018 end-page: 517 article-title: ACG clinical guideline: Management of Crohn's disease in adults publication-title: Am J Gastroenterol – volume: 23 start-page: 5836 issue: 32 year: 2017 end-page: 5848 article-title: Ophthalmic manifestations in patients with inflammatory bowel disease: a review publication-title: World J Gastroenterol – volume: 4 start-page: 160 issue: 2 year: 1949 end-page: 167 article-title: Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer publication-title: Blood – volume: 35 start-page: 453 issue: 5 year: 1996 end-page: 457 article-title: Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis publication-title: Br J Rheumatol – volume: 175 start-page: 23 issue: 1 year: 2016 end-page: 44 article-title: British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016 publication-title: Br J Dermatol – volume: 61 start-page: 451 issue: 3 year: 2009 end-page: 485 article-title: Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents publication-title: J Am Acad Dermatol – volume: 12 issue: 6 year: 2023 article-title: The optimal management of inflammatory bowel disease in patients with cancer publication-title: J Clin Med – volume: 16 start-page: 693 issue: 4 year: 2002 end-page: 697 article-title: The efficacy of methotrexate for maintaining remission in inflammatory bowel disease publication-title: Aliment Pharmacol Ther – volume: 161 start-page: 1118 issue: 4 year: 2021 end-page: 1132 article-title: Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management publication-title: Gastroenterology – volume: 59 start-page: 1363 issue: 10 year: 2010 end-page: 1368 article-title: Usefulness of co‐treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy publication-title: Gut – volume: 46 start-page: 1724 issue: 27 year: 1999 end-page: 1729 article-title: Methotrexate in Crohn's disease: results of a randomized, double‐blind, placebo‐controlled trial publication-title: Hepato‐Gastroenterology – volume: 25 start-page: 36 issue: 1 year: 1998 end-page: 43 article-title: The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials publication-title: J Rheumatol – volume: 61 start-page: 331 issue: 1 year: 2021 end-page: 336 article-title: Effectiveness and tolerability of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis publication-title: Rheumatology (Oxford) – volume: 35 start-page: 284 issue: 2 year: 2012 end-page: 291 article-title: Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single‐centre experience publication-title: Aliment Pharmacol Ther – volume: 37 start-page: 340 issue: 3 year: 2013 end-page: 345 article-title: Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease publication-title: Aliment Pharmacol Ther – volume: 56 start-page: 865 issue: 6 year: 2017 end-page: 868 article-title: BSR and BHPR guideline for the prescription and monitoring of non‐biologic disease‐modifying anti‐rheumatic drugs publication-title: Rheumatology – volume: 18 start-page: 359 issue: 2 year: 2012 end-page: 367 article-title: Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta‐analysis of clinical trials publication-title: Inflamm Bowel Dis – volume: 14 start-page: 4 issue: 1 year: 2020 end-page: 22 article-title: ECCO guidelines on therapeutics in Crohn's disease: medical treatment publication-title: J Crohns Colitis – volume: 35 start-page: 619 issue: 9 year: 2003 end-page: 627 article-title: Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator‐blind study publication-title: Dig Liver Dis – volume: 12 start-page: 311 issue: 4 year: 2006 end-page: 327 article-title: Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD publication-title: Inflamm Bowel Dis – volume: 24 start-page: 1558 issue: 7 year: 2018 end-page: 1565 article-title: Methotrexate and Thioguanine rescue therapy for conventional thiopurine failing ulcerative colitis patients: a multi‐center database study on tolerability and effectiveness publication-title: Inflamm Bowel Dis – volume: 14 year: 2021 article-title: Short‐term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn's disease: a retrospective study publication-title: Ther Adv Gastroenterol – volume: 143 start-page: 390 issue: 2 year: 2012 end-page: 399 article-title: Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease publication-title: Gastroenterology – volume: 64 start-page: 1622 issue: 6 year: 2019 end-page: 1631 article-title: Higher mucosal healing with tumor necrosis factor inhibitors in combination with thiopurines compared to methotrexate in Crohn's disease publication-title: Dig Dis Sci – volume: 9 start-page: 312 issue: 4 year: 2015 end-page: 317 article-title: Optimal doses of methotrexate combined with anti‐TNF therapy to maintain clinical remission in inflammatory bowel disease publication-title: J Crohns Colitis – volume: 15 year: 2022 article-title: Evidence‐based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications publication-title: Ther Adv Gastroenterol – volume: 86 start-page: 208 issue: 1014 year: 2010 end-page: 211 article-title: Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment publication-title: Postgrad Med J – volume: 6 start-page: 328 issue: 6 year: 2015 end-page: 338 article-title: Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti‐inflammatory drugs, traditional disease‐modifying antirheumatic drugs and biological therapies publication-title: Ther Adv Chronic Dis – volume: 160 start-page: 622 issue: 3 year: 2009 end-page: 628 article-title: Effect of folic or folinic acid supplementation on methotrexate‐associated safety and efficacy in inflammatory disease: a systematic review publication-title: Br J Dermatol – volume: 2014 issue: 6 year: 2014 article-title: Methotrexate for treating rheumatoid arthritis publication-title: Cochrane Database Syst Rev – volume: 78 start-page: 989 issue: 5 year: 2023 end-page: 997 article-title: Risk of liver fibrosis associated with long‐term methotrexate therapy may be overestimated publication-title: J Hepatol – volume: 78 start-page: 896 issue: 5 year: 2023 end-page: 897 article-title: Methotrexate‐induced liver fibrosis: the end of a long‐held belief publication-title: J Hepatol – volume: 19 start-page: 96 issue: 2 year: 2023 end-page: 110 article-title: Busting the myth of methotrexate chronic hepatotoxicity publication-title: Nat Rev Rheumatol – volume: 150 start-page: 380 issue: 2 year: 2016 end-page: 388.e4 article-title: Methotrexate is not superior to placebo for inducing steroid‐free remission, but induces steroid‐free clinical remission in a larger proportion of patients with ulcerative colitis publication-title: Gastroenterology – volume: 110 start-page: 353 issue: 5 year: 1989 end-page: 356 article-title: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease publication-title: Ann Intern Med – volume: 18 year: 2023 article-title: ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease publication-title: J Crohns Colitis – volume: 160 start-page: 445 issue: 1 year: 2021 end-page: 451 article-title: AGA clinical practice update on management of inflammatory bowel disease in elderly patients: expert review publication-title: Gastroenterology – volume: 41 start-page: 2701 issue: 9 year: 2022 end-page: 2712 article-title: Oral methotrexate at doses 15‐25 mg/week is non‐inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta‐analysis publication-title: Clin Rheumatol – volume: 2 start-page: 24 issue: 1 year: 2008 end-page: 62 article-title: European evidence‐based consensus on the management of ulcerative colitis: current management publication-title: J Crohns Colitis – volume: 134 start-page: 929 issue: 4 year: 2008 end-page: 936 article-title: Risk factors for opportunistic infections in patients with inflammatory bowel disease publication-title: Gastroenterology – volume: 30 start-page: 614 issue: 6 year: 2009 end-page: 620 article-title: Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine publication-title: Aliment Pharmacol Ther – volume: 14 issue: 9 year: 2019 article-title: Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta‐analysis publication-title: PLoS One – volume: 145 start-page: 927 issue: 5 year: 2013 end-page: 930 article-title: Lymphoma: the Bête noire of the long‐term use of thiopurines in adult and elderly patients with inflammatory bowel disease publication-title: Gastroenterology – volume: 78 start-page: 383 issue: 2 year: 2018 end-page: 394 article-title: Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation publication-title: J Am Acad Dermatol – volume: 28 start-page: 24 issue: 1 year: 2013 end-page: 30 article-title: Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review publication-title: J Gastroenterol Hepatol – volume: 14 start-page: 4 issue: 1 year: 2021 end-page: 11 article-title: Pregnancy and medications in inflammatory bowel disease publication-title: Obstet Med – volume: 146 start-page: 681 issue: 3 year: 2014 end-page: 688.e1 article-title: Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease publication-title: Gastroenterology – volume: 116 start-page: 215 issue: 2 year: 1980 end-page: 217 article-title: Psoriasis, methotrexate, and oligospermia publication-title: Arch Dermatol – volume: 66 start-page: 1101 issue: 5 year: 2014 end-page: 1110 article-title: Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study publication-title: Arthritis Rheumatol – volume: 96 start-page: 220 issue: 4 year: 2017 end-page: 227 article-title: Efficacy, safety and mucosal healing of methotrexate in a large longitudinal cohort of inflammatory bowel disease patients publication-title: Digestion – volume: 22 start-page: 224 issue: 1 year: 2016 end-page: 233 article-title: Use of methotrexate in the treatment of inflammatory bowel diseases publication-title: Inflamm Bowel Dis – volume: 44 start-page: 1515 issue: 7 year: 2001 end-page: 1524 article-title: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty‐eight week, multicenter, randomized, double‐blind, placebo‐controlled study publication-title: Arthritis Rheum – volume: 25 start-page: 197 issue: 5 year: 2019 end-page: 202 article-title: Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review publication-title: J Clin Rheumatol – volume: 155 start-page: 1098 issue: 4 year: 2018 end-page: 1108.e9 article-title: Methotrexate is not superior to placebo in maintaining steroid‐free response or remission in ulcerative colitis publication-title: Gastroenterology – volume: 106 start-page: 110 issue: 1 year: 2011 end-page: 119 article-title: Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort publication-title: Am J Gastroenterol – volume: 56 start-page: 1226 issue: 9 year: 2007 end-page: 1231 article-title: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease publication-title: Gut – volume: 24 start-page: 173 issue: 3 year: 2011 end-page: 180 article-title: Rheumatological manifestations in inflammatory bowel disease publication-title: Ann Gastroenterol – volume: 99 start-page: 3909 issue: 11 year: 2002 end-page: 3915 article-title: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3‐year prospective study in France publication-title: Blood – volume: 82 start-page: 19 issue: 1 year: 2023 end-page: 34 article-title: ASAS‐EULAR recommendations for the management of axial spondyloarthritis: 2022 update publication-title: Ann Rheum Dis – volume: 76 start-page: 787 issue: 902 year: 2000 end-page: 789 article-title: Safety of low dose methotrexate in elderly patients with rheumatoid arthritis publication-title: Postgrad Med J – volume: 13 start-page: 990 issue: 8 year: 2019 end-page: 995 article-title: Low‐dose methotrexate has similar outcomes to high‐dose methotrexate in combination with anti‐TNF therapy in inflammatory bowel diseases publication-title: J Crohns Colitis – volume: 17 start-page: 1680 issue: 9 year: 2019 end-page: 1713 article-title: Canadian Association of Gastroenterology Clinical Practice Guideline for the management of luminal Crohn's disease publication-title: Clin Gastroenterol Hepatol – volume: 40 start-page: 233 issue: 3 year: 2010 end-page: 240 article-title: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis publication-title: Semin Arthritis Rheum – volume: 4 start-page: 341 issue: 5 year: 2019 end-page: 353 article-title: Predictors of anti‐TNF treatment failure in anti‐TNF‐naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study publication-title: Lancet Gastroenterol Hepatol – volume: 11 start-page: 569 issue: 3 year: 1997 end-page: 573 article-title: The absorption of low‐dose methotrexate in patients with inflammatory bowel disease publication-title: Aliment Pharmacol Ther – volume: 24 start-page: 1086 issue: 9 year: 2012 end-page: 1091 article-title: Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long‐term efficacy and safety. The Madrid experience publication-title: Eur J Gastroenterol Hepatol – volume: 5 start-page: 397 issue: 5 year: 2011 end-page: 401 article-title: Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy publication-title: J Crohns Colitis – volume: 7 start-page: 51 issue: 1 year: 2016 end-page: 65 article-title: Elderly patients and inflammatory bowel disease publication-title: World J Gastrointest Pharmacol Ther – volume: 9 start-page: 945 issue: 11 year: 2015 end-page: 965 article-title: European evidence‐based consensus: inflammatory bowel disease and malignancies publication-title: J Crohns Colitis – volume: 68 start-page: 1086 issue: 7 year: 2009 end-page: 1093 article-title: Multinational evidence‐based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative publication-title: Ann Rheum Dis – volume: 95 start-page: 1730 issue: 7 year: 2000 end-page: 1734 article-title: Methotrexate in Crohn's disease: long‐term efficacy and toxicity publication-title: Am J Gastroenterol – volume: 52 start-page: 1174 issue: 7 year: 2020 end-page: 1184 article-title: Thiopurines vs methotrexate: comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease publication-title: Aliment Pharmacol Ther – volume: 21 start-page: 385 issue: 4 year: 2005 end-page: 389 article-title: Oral methotrexate in ulcerative colitis publication-title: Aliment Pharmacol Ther – volume: 342 start-page: 1627 issue: 22 year: 2000 end-page: 1632 article-title: A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators publication-title: N Engl J Med – volume: 19 start-page: 1366 issue: 7 year: 2021 end-page: 1376.e2 article-title: Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab publication-title: Clin Gastroenterol Hepatol – volume: 25 start-page: 4158 issue: 30 year: 2019 end-page: 4171 article-title: Elderly patients with inflammatory bowel disease: updated review of the therapeutic landscape publication-title: World J Gastroenterol – ident: e_1_2_10_81_1 doi: 10.1053/gast.1996.v110.pm8613046 – ident: e_1_2_10_41_1 doi: 10.1111/j.1365‐2133.2008.08876.x – ident: e_1_2_10_48_1 doi: 10.1097/00042737‐200012110‐00010 – ident: e_1_2_10_73_1 doi: 10.1016/j.jaad.2017.06.043 – ident: e_1_2_10_28_1 doi: 10.1111/apt.12161 – ident: e_1_2_10_56_1 doi: 10.1007/s10620‐018‐5422‐8 – ident: e_1_2_10_23_1 doi: 10.1111/j.1365‐2036.2011.04925.x – ident: e_1_2_10_101_1 doi: 10.1097/MEG.0b013e3283556db5 – ident: e_1_2_10_51_1 doi: 10.1016/s1590‐8658(03)00372‐4 – ident: e_1_2_10_12_1 doi: 10.1016/j.crohns.2007.11.002 – ident: e_1_2_10_43_1 doi: 10.1634/theoncologist.2015‐0164 – ident: e_1_2_10_60_1 doi: 10.1111/j.1365‐2036.2005.02331.x – ident: e_1_2_10_27_1 doi: 10.3390/jcm12134382 – ident: e_1_2_10_49_1 doi: 10.1038/ajg.2018.27 – ident: e_1_2_10_36_1 doi: 10.1002/14651858.CD000951.pub2 – ident: e_1_2_10_102_1 doi: 10.4292/wjgpt.v7.i1.51 – ident: e_1_2_10_91_1 doi: 10.1016/j.jhep.2022.12.034 – ident: e_1_2_10_53_1 doi: 10.1016/S2468‐1253(19)30012‐3 – ident: e_1_2_10_37_1 doi: 10.1002/1529‐0131(200107)44:7<1515::AID‐ART273>3.0.CO;2‐7 – ident: e_1_2_10_26_1 doi: 10.1093/ecco‐jcc/jjv027 – ident: e_1_2_10_20_1 doi: 10.1046/j.1365‐2036.2002.01227.x – ident: e_1_2_10_14_1 doi: 10.1093/ecco‐jcc/jjab178 – ident: e_1_2_10_24_1 doi: 10.1016/j.cgh.2012.12.026 – ident: e_1_2_10_109_1 doi: 10.1093/ecco‐jcc/jjv141 – ident: e_1_2_10_94_1 doi: 10.1053/j.gastro.2006.04.049 – ident: e_1_2_10_29_1 doi: 10.1046/j.1365‐2036.1997.00175.x – ident: e_1_2_10_7_1 doi: 10.1002/14651858.CD000957.pub2 – ident: e_1_2_10_45_1 doi: 10.1111/bjd.14816 – ident: e_1_2_10_50_1 doi: 10.1016/j.cgh.2019.02.043 – ident: e_1_2_10_30_1 doi: 10.1177/17562848221085889 – ident: e_1_2_10_6_1 doi: 10.1111/apt.17719 – ident: e_1_2_10_55_1 doi: 10.1136/gut.2010.212712 – ident: e_1_2_10_115_1 doi: 10.1053/j.gastro.2013.09.035 – ident: e_1_2_10_85_1 doi: 10.1053/j.gastro.2008.01.012 – ident: e_1_2_10_104_1 doi: 10.1053/j.gastro.2020.08.060 – ident: e_1_2_10_44_1 doi: 10.1136/ard.2008.094474 – ident: e_1_2_10_92_1 doi: 10.1093/rheumatology/keab313 – ident: e_1_2_10_107_1 doi: 10.1111/jgh.12015 – ident: e_1_2_10_8_1 doi: 10.1177/2040622315608647 – ident: e_1_2_10_25_1 doi: 10.1093/ecco‐jcc/jjz020 – ident: e_1_2_10_65_1 doi: 10.1053/j.gastro.2021.07.042 – ident: e_1_2_10_76_1 doi: 10.1016/j.semarthrit.2010.04.003 – ident: e_1_2_10_110_1 doi: 10.1177/1756284818817293 – ident: e_1_2_10_64_1 doi: 10.1016/j.crohns.2011.03.012 – ident: e_1_2_10_86_1 doi: 10.1097/MIB.0000000000000589 – ident: e_1_2_10_5_1 doi: 10.1097/01.MIB.0000209787.19952.53 – ident: e_1_2_10_93_1 doi: 10.1177/1753495X20919214 – ident: e_1_2_10_52_1 doi: 10.1053/j.gastro.2013.11.024 – ident: e_1_2_10_106_1 doi: 10.1182/blood.v99.11.3909 – volume: 92 start-page: 2203 issue: 12 year: 1997 ident: e_1_2_10_18_1 article-title: Methotrexate in chronic active Crohn's disease: a double‐blind, randomized Israeli multicenter trial publication-title: Am J Gastroenterol – ident: e_1_2_10_96_1 doi: 10.1001/archderm.1980.01640260091025 – ident: e_1_2_10_58_1 doi: 10.1007/s00384‐023‐04349‐1 – ident: e_1_2_10_54_1 doi: 10.1136/gut.2006.099978 – ident: e_1_2_10_83_1 doi: 10.1177/17562848211043017 – ident: e_1_2_10_3_1 doi: 10.1038/ncpgasthep0796 – ident: e_1_2_10_114_1 doi: 10.1001/jama.2017.16071 – ident: e_1_2_10_63_1 doi: 10.1159/000482007 – volume: 25 start-page: 36 issue: 1 year: 1998 ident: e_1_2_10_42_1 article-title: The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials publication-title: J Rheumatol – ident: e_1_2_10_113_1 – ident: e_1_2_10_87_1 doi: 10.3109/00365521.2011.647412 – volume: 24 start-page: 173 issue: 3 year: 2011 ident: e_1_2_10_68_1 article-title: Rheumatological manifestations in inflammatory bowel disease publication-title: Ann Gastroenterol – ident: e_1_2_10_62_1 doi: 10.1053/j.gastro.2018.06.046 – ident: e_1_2_10_77_1 doi: 10.1002/art.23835 – ident: e_1_2_10_72_1 doi: 10.1016/j.jaad.2016.08.022 – ident: e_1_2_10_33_1 doi: 10.1002/acr.24596 – ident: e_1_2_10_46_1 doi: 10.1093/rheumatology/kew479 – ident: e_1_2_10_79_1 doi: 10.1002/ibd.21820 – ident: e_1_2_10_34_1 – ident: e_1_2_10_105_1 doi: 10.1093/ecco‐jcc/jjw188 – ident: e_1_2_10_35_1 doi: 10.1111/j.1440‐1746.2007.05006.x – ident: e_1_2_10_90_1 doi: 10.1016/j.jhep.2023.02.018 – ident: e_1_2_10_16_1 doi: 10.1056/NEJM199502023320503 – ident: e_1_2_10_61_1 doi: 10.1053/j.gastro.2015.10.050 – ident: e_1_2_10_31_1 doi: 10.1007/s10067‐022‐06221‐z – volume: 46 start-page: 1724 issue: 27 year: 1999 ident: e_1_2_10_19_1 article-title: Methotrexate in Crohn's disease: results of a randomized, double‐blind, placebo‐controlled trial publication-title: Hepato‐Gastroenterology – ident: e_1_2_10_2_1 doi: 10.1182/blood.V4.2.160.160 – ident: e_1_2_10_74_1 doi: 10.1016/j.jaad.2020.02.044 – ident: e_1_2_10_21_1 doi: 10.1111/j.1365‐2036.2009.04073.x – ident: e_1_2_10_78_1 doi: 10.3748/wjg.v23.i32.5836 – ident: e_1_2_10_82_1 doi: 10.1093/ibd/izy047 – ident: e_1_2_10_89_1 doi: 10.1038/s41584‐022‐00883‐4 – ident: e_1_2_10_15_1 doi: 10.1007/s11938‐017‐0128‐0 – ident: e_1_2_10_71_1 doi: 10.3390/jcm10020364 – ident: e_1_2_10_67_1 doi: 10.1038/ajg.2010.343 – ident: e_1_2_10_9_1 doi: 10.1016/j.jaad.2009.03.027 – ident: e_1_2_10_10_1 doi: 10.7326/0003‐4819‐110‐5‐353 – ident: e_1_2_10_69_1 doi: 10.1093/ecco‐jcc/jjad108 – ident: e_1_2_10_98_1 doi: 10.1136/pmj.76.902.787 – ident: e_1_2_10_111_1 doi: 10.3390/jcm12062432 – ident: e_1_2_10_40_1 doi: 10.1016/j.clnu.2022.12.004 – ident: e_1_2_10_75_1 doi: 10.1016/j.autrev.2013.06.005 – ident: e_1_2_10_13_1 doi: 10.1093/ecco‐jcc/jjz180 – ident: e_1_2_10_47_1 doi: 10.1371/journal.pone.0194401 – ident: e_1_2_10_103_1 doi: 10.3748/wjg.v25.i30.4158 – ident: e_1_2_10_112_1 doi: 10.1111/apt.13862 – ident: e_1_2_10_99_1 doi: 10.1093/rheumatology/35.5.453 – ident: e_1_2_10_22_1 doi: 10.1136/pgmj.2009.085787 – ident: e_1_2_10_32_1 doi: 10.1371/journal.pone.0221823 – ident: e_1_2_10_80_1 doi: 10.1111/apt.16039 – ident: e_1_2_10_4_1 doi: 10.4065/71.1.69 – ident: e_1_2_10_84_1 doi: 10.1111/j.1572‐0241.2000.02190.x – ident: e_1_2_10_97_1 doi: 10.3899/jrheum.100600 – ident: e_1_2_10_66_1 doi: 10.1136/gutjnl‐2020‐322129 – ident: e_1_2_10_70_1 doi: 10.1136/ard‐2022‐223296 – ident: e_1_2_10_39_1 doi: 10.1016/j.dld.2011.09.015 – ident: e_1_2_10_88_1 doi: 10.1111/j.1365‐2036.2006.02929.x – ident: e_1_2_10_95_1 doi: 10.1002/art.38368 – ident: e_1_2_10_17_1 doi: 10.1056/NEJM200006013422202 – ident: e_1_2_10_57_1 doi: 10.1093/ecco‐jcc/jjaa050 – ident: e_1_2_10_11_1 doi: 10.1136/gut.2005.081950b – ident: e_1_2_10_38_1 doi: 10.1097/RHU.0000000000000810 – ident: e_1_2_10_59_1 doi: 10.1016/j.cgh.2020.07.012 – ident: e_1_2_10_108_1 doi: 10.1053/j.gastro.2012.05.004 – ident: e_1_2_10_100_1 doi: 10.1093/rheumatology/kep291 |
SSID | ssj0006702 |
Score | 2.4777937 |
SecondaryResourceType | review_article |
Snippet | Summary
Background
Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared... Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines. To... BackgroundMethotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to... Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 686 |
SubjectTerms | Cirrhosis Clinical trials Crohn's disease Fibrosis Immunogenicity Inflammatory bowel disease Inflammatory bowel diseases Intestine Liver diseases Methotrexate Observational studies Remission Remission (Medicine) Steroids Systematic review Tumor necrosis factor Tumor necrosis factor-TNF Ulcerative colitis |
Title | Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fapt.18194 https://www.ncbi.nlm.nih.gov/pubmed/39076140 https://www.proquest.com/docview/3097497664 https://www.proquest.com/docview/3086064828 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVEBS databaseName: Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1365-2036 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0006702 issn: 0269-2813 databaseCode: ABDBF dateStart: 19980101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1365-2036 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006702 issn: 0269-2813 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0269-2813 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1365-2036 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006702 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9UwFD6MsxA3vh93HIcoLtz00iZpkurqIg6DcGXQGZiFUPIE8dpe7m1xdOWP8Bf6S8yjrY4PEKGLlqQ0zTkn-U7OyReAx9TqSmmtM0oNzqhQKpMhaZw6J5l1wQsJSwPLV-zolL48K8924Nm4FybxQ0wLbsEy4ngdDFyq7U9GLtfd3E9PVeACLUgZQ7Svf1BHMR7zDb2LUWVYFGRgFQpZPNObF-ei3wDmRbwaJ5zDa_B2bGrKM3k_7zs1159_YXH8z3-5DlcHIIoWSXNuwI5tbsLl5RBqvwWrNxPHM0r7W56iZThuutvYcw9Qv335ukDrtt2sPqE-7ZBpW4NkY9Jjv7UGxch9lD16Fy7n9e9DjOsj1X60KzTEh27D6eGLk-dH2XA0Q6aJEDTjpWacWqKE5AF1CCtV4bBlgc7ecWOwcAJzrU2huJK50rkSWMqidFUupSJ3YLdpG3sPEPODgCkqSTBxftSuFC8Zd4XGOTUei7IZPBmFVOuBtzwcn7GqR__F914de28Gj6aq60TW8adK-6Ok68FetzXJvV_lkRnzxQ-nYm9pIXwiG9v2oY7w3h71LuoM7iYNmb5CqrAeRHPf2Cjnv3--XhyfxJu9f696H65gj6VSats-7Hab3j7wWKhTB3AJ0-ODqPrfAQlrCCY |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEB6SFJpeQpo07aZpo5YeenGwZa0kl1yWkrBNsiHQDeRm9ITC1l72Qdtbf0R_YX5JRrLXJDSFgg82GiMxo5G-eWgE8IE5U2hjTMKYpQmTWicqJI0z7xV3PlghwTUwuuTDa3Z2079Zg-PVWZimPkTncAuaEdfroODBIX1Py9V0cYT7U8HW4QnjNA1zmrKrbh3mImYcopFRJFRmeVtXKOTxdL8-3I3-gpgPEWvcck63YavFimTQCPc5rLlqB56O2mj4Lky-dmWYSXME5RMZhRuhFzP3EzHk7e8_AzKt69nkF1k2h1jq2hJV2eZzOXeWxOB6FA_5Fh6PU-R7DL0TXf9wE9KGcF7A9enJ-PMwaW9PSEwuJUtE33DBXK6lEgEYSKd05qnjoeK8F9ZS6SUVxthMC61SbVItqVJZ3xepUjrfg42qrtwrIBz11GaFymnucWEttOhz4TNDU2YRLvIefFxxsTRtafFww8WkXJkYyPAyMrwH7zvSaVNP4zGig5Uoylal5mWeoumD4Ilj87uuGZUhRDhU5eploJFokDG0InvwshFh10teBJcNS3GwUab_7r4cXI3jy_7_kx7C5nA8uigvvlyev4ZnFKFPk4l2ABuL2dK9Qeiy0G_jDL0D0Urqmw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVcKM-yUMAgDlyyShyv7cBpVViVx1YVtFIPSJGfEmJJVttEBU78iP7C_pL6kQTKQ0JIOSSyozieGfsbz_gzwBNiVCGVUgkhGieES5kInzROrBXUWO-F-KWB-R7dPSSvjyZHa_C83wsT-SGGBTdvGWG89ga-1PYnIxfLZuymp4JcgsuEOu_KI6J3P7ijKAsJh87HKBLMs7yjFfJpPMOrFyej3xDmRcAaZpzZJnzo2xoTTT6N20aO1bdfaBz_82euwdUOiaJpVJ3rsGaqG7Ax72LtN2HxfiB5RnGDyzM09-dNNyvzxSHUs--nU7Ss69XiK2rjFpm61khUOj62x0ajELoPwkcf_WWdAn4OgX0k6xOzQF2A6BYczl4e7Owm3dkMico5JwmbKMqIySUXzMMOboTMLDbU89lbpjXmlmOmlM4kkyKVKpUcC5FNbJEKIfPbsF7VlbkDiLpRQGeFyHFu3bBdSDahzGYKp0Q7MEpH8LQXUqk64nJ_fsai7B0Y13tl6L0RPB6qLiNbx58qbfeSLjuDPS7z1DlWDppRV_xoKHam5uMnojJ16-tw5-4R56OOYCtqyPCVvPALQiR1jQ1y_vvny-n-Qbi5--9VH8LG_otZ-fbV3pt7cAU7XBXT3LZhvVm15r7DRY18EPT_HB2zCho |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systematic+review%3A+Methotrexate-A+poorly+understood+and+underused+medication+in+inflammatory+bowel+disease&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Sequier%2C+L%C3%A9a&rft.au=Caron%2C+B%C3%A9n%C3%A9dicte&rft.au=Loeuille%2C+Damien&rft.au=Honap%2C+Sailish&rft.date=2024-09-01&rft.issn=1365-2036&rft.eissn=1365-2036&rft.volume=60&rft.issue=6&rft.spage=686&rft_id=info:doi/10.1111%2Fapt.18194&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon |